Clinical Trials Logo

Angioplasty, Balloon, Coronary clinical trials

View clinical trials related to Angioplasty, Balloon, Coronary.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05750927 Completed - Clinical trials for Coronary Artery Disease

Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes

ASCOP
Start date: December 1, 2022
Phase:
Study type: Observational

To describe the prevalence and clinical features of patients with severe aortic stenosis undergoing TAVI and concomitant clinically indicated, complex and/or high-risk PCI

NCT ID: NCT03085823 Completed - Clinical trials for Percutaneous Coronary Intervention

The All-comers Sirolimus-coated Balloon European Registry

EASTBOURNE
Start date: September 2016
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to observe and evaluate the performance of a Sirolimus-eluting Drug Coated Balloon for the treatment of any type of coronary lesions, including native vessel disease and in stent restenosis.

NCT ID: NCT02808767 Completed - Clinical trials for Myocardial Infarction

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

PRAGUE-18
Start date: January 2013
Phase: Phase 4
Study type: Interventional

This study evaluates the efficacy of Prasugrel and Ticagrelor in the treatment of acute myocardial infarction.

NCT ID: NCT02575092 Completed - Hypertension Clinical Trials

The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment

CONTRAST-CADT
Start date: November 1, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Contrast-induced nephropathy has become the third-largest cause of hospital acquired acute renal injury, and which morbidity is only less than that of renal hypoperfusion and renal toxicity of drugs, about 11%of all cases. Pathophysiologic mechanisms of contrast-induced nephropathy(CIN) is not entirely clear yet. May be associated with renal hemodynamic changes, medullary ischemia because of renal blood flow reduction, oxidative stress, endothelial dysfunction ,contrast agents damage the epithelium of renal tubular directly and so on. Currently the studies have proved that inflammation(CRP, TNF-α and NF-қB) played a role in CIN.It is well-know that the hyperhomocysteinemia(HHCY) is a independent risk factor for cardiovascular diseases, which has pro-inflammatory effects. Researches showed that Hcy stimulated CRP generation by the NMDAr-ROS-ERK1 / 2 / p38-NF-қB signaling pathway and triggered inflammatory response. We will compare the CIN incidence of different plasma Hcy levels in adults hypertensive patients undergoing coronary artery diagnosis and treatment(CAG and PCI). CIN was defined as an absolute ≥0.5mg/dl or a relative ≥25% increase in the serum creatinine level at 48 hours after the procedure. The relationship between decreased plasma Hcy levels and blood pressure values by using Enalapril Maleate and Folic Acid Tablets(as the program-based antihypertension) and recovery of CIN has been observed. Using univariate and multivariate Logistic regression to analyse the relationship between HHcy and CIN, and taking receiver operating characteristic (ROC) curve to select the best Hcy plasma levels that which can predict the CIN and the probability. This study will help us to understand the relationship between HHcy and CIN that course of the procedure in adults hypertensive patients, preoperative plasma Hcy levels can predict the incidence of CIN and whether Enalapril Maleate Folic Acid tablets can reduce the CIN of hypertensive patients with HHcy. Which has important clinical significance. This study also offer feasibility for further research that HHcy plays a role in pathogenesis and specific signaling pathways of CIN.